Top-News
Gesundheitswesen USA

Brainstorm Cell Therapeutics Inc News

Aktie
WKN:  A12BXW ISIN:  US10501E2019 US-Symbol:  BCLI
0,463 €
-0,0075 €
-1,59%
31.05.24 17:56:08
Handeln Depot/Watchlist
Aktienanzahl *
48,98 Mio.
Marktkapitalisierung *
21,97 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 13.03.2024

Brainstorm Cell Therapeutics Inc News

20.05.24 - PR Newswire
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-​Term Treatment with NurOwn PR Newswire
14.05.24 - PR Newswire
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire
16.04.24 - PR Newswire
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn PR Newswire
11.04.24 - PR Newswire
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire
10.04.24 - PR Newswire
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
BrainStorm Cell Therapeutics Announces Peer-​reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS PR Newswire
09.04.24 - PR Newswire
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS PR Newswire
08.04.24 - PR Newswire
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program PR Newswire
01.04.24 - PR Newswire
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update PR Newswire
27.02.24 - PR Newswire
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference PR Newswire
23.02.24 - PR Newswire
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS PR Newswire
13.02.24 - PR Newswire
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum PR Newswire
02.01.24 - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire
30.12.23 - PR Newswire
BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm - BCLI
BCLI FINAL DEADLINE TUESDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure ...
28.12.23 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI PR Newswire
28.12.23 - PR Newswire
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Brainstorm To Contact Him Directly To Discuss Their Options
BRAINSTORM INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In ...
27.12.23 - PR Newswire
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit
BCLI Investors Have Opportunity to Lead Brainstorm Cell Therapeutics Inc. Securities Fraud Lawsuit PR Newswire
27.12.23 - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire
26.12.23 - PR Newswire
BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
BrainStorm Granted Patents for Allogeneic Exosome Platform-​Product in Neurological Disorder Treatments PR Newswire
26.12.23 - PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc.(BCLI) Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire
23.12.23 - PR Newswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities ...

Newssuche

Videos

newspaper
29.05.24
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »